



BACKGROUND

SEMPRUS BIOSCIENCES: THE COMPANY

Semprus BioSciences, headquartered in Cambridge, Massachusetts, is a venture-backed biomedical company with a dual mission: to provide complication-free medical devices designed to preserve patients' long-term health and quality-of-life and to contribute to health care cost efficiencies. Our innovative, multi-faceted approach to durable surface modifications signifies a breakthrough in medical device technology. Our current focus is to enable the first permanently dual-functional (anti-colonization and anti-thrombogenic) vascular access catheter with a single surface modification.

Founded out of the Massachusetts Institute of Technology's Langer Lab, the company has developed the next-generation biofunctional surface platform – which is focused on achieving clinical benefits that far exceed current market offerings containing silver, heparin, and antibiotic coatings. Through covalent chemical bonding of our Semprus Surfaces™, a permanent non-leaching biomaterial modification to the device surface, our technology is expected to vastly improve patient outcomes by preventing serious medical complications, such as infection, blood clots, improper healing, and cell overgrowth. We have assembled a world class product development team – scientists, industry executives and clinical experts – who specialize in reducing such complications at the confluence of the human body and implantable devices.

In December 2008, Semprus BioSciences completed an \$8 million Series A Financing co-led by 5AM Ventures and Pangaea Ventures. This funding came on the heels of our \$2.5 million seed capital raised in 2007. We have worldwide licenses secured from the Massachusetts Institute of Technology and the University of Washington, and hold numerous proprietary intellectual property filings. Our laboratory and office complex is located in Kendall Square, Cambridge's innovative biomedical center, and employs 18 full-time professionals.